Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Gilead wins US patent tri­al over HIV pre­ven­tion drugs

A fed­er­al ju­ry ruled in fa­vor of Gilead on Tues­day in a long-run­ning patent bat­tle over the use of its HIV drugs Tru­va­da and De­scovy for pre-ex­po­sure pro­phy­lax­is (PrEP).

While Tru­va­da and De­scovy were ini­tial­ly ap­proved for the treat­ment of HIV in 2004 and 2016, re­spec­tive­ly, they each won ap­provals years lat­er in the pre­ven­ta­tive set­ting. The US filed suit against Gilead in 2019, al­leg­ing that the com­pa­ny “ig­nored CDC’s clear con­tri­bu­tions and base­less­ly de­nied the va­lid­i­ty of CDC’s patents” in grow­ing its PrEP fran­chise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.